Physician profile
Patrick M Reidy
NPI 1194752840
$8,865.34
in general payments reported to CMS, 2019-2025
28 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 86% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $931 · 2021: $1,162 · 2022: $1,616 · 2023: $1,534 · 2024: $1,289 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,254 · Education: $56.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,254.43 |
| Education | $56.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,430.56 | 2019-2025 | Jot Dx |
| Genzyme Corporation | $1,312.33 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $940.99 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $854.55 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $562.44 | 2019-2025 | Tezspire, Fasenra |
| Genentech USA, INC. | $359.10 | 2019-2025 | Xolair |
| Medtronic, INC. | $331.72 | 2021-2025 | Propel |
| Acclarent, INC | $270.17 | 2019-2023 | Relieva Spinplus |
| Optinose US, INC. | $249.56 | 2019-2025 | |
| Stryker Corporation | $236.96 | 2019-2025 | Xpress Loprofile |
| Medtronic USA, INC. | $188.23 | 2020 | |
| Intersect Ent, INC. | $181.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $161.71 | 2020-2024 | |
| Neurent Medical Limited | $151.88 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Kaleo, INC. | $138.64 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xoran Technologies LLC | $88.33 | 2021 | |
| Aerin Medical INC. | $87.49 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $56.95 | 2023 | |
| Organogenesis INC. | $51.71 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $44.49 | 2021-2023 | |
| Baudax Bio INC. | $42.54 | 2021-2022 | |
| Heron Therapeutics, INC. | $24.54 | 2024 | Aponvie |
| Hikma Pharmaceuticals USA | $19.61 | 2023 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $18.12 | 2025 | Xhance |
| Integra Lifesciences Corporation | $16.62 | 2023 | Integra, Integra Duo, Instruments-Orthopedic |
| Eyevance Pharmaceuticals LLC | $16.09 | 2021 | |
| Phadia US INC. | $15.29 | 2023 | Immunocap |
| Alk-Abello, INC | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Reidy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.